Member Info for lambo222

Over £300k bought today, just shows how ridiculously off the radar and undervalued this is! I wouldn’t be surprised if this goes on a huge run over the next few weeks with pharma companies anything is possible and this one ticks all the boxes, multibillion $ sales potential, world class US partner funding the phase 3 trial, fully funded, low Mcap, and all time low price, if this gets going there will be no stopping it after 3 years in the doldrums the next 2 weeks will decide the future of IMM, 10 days to go… GL all

It’s been delay after delay for 3 years due to Covid and PK study requirement, but we are now less than 2 weeks away from potentially transformational news in which the share price can easily hit 15p, huge buying pressure today well over £400k traded biggest volume for months, once they let this go it’s going to be epic especially on a positive FDA decision, GL to all those invested

Short term traders will take their positions as not many opportunities to make a few hundred % profit in such a short space of time, FDA approval on 29th August which is 8 trading days away will unlock partnering discussions for the rest of the world, it will unlock the CIDP phase 3 trial which is ready to go, and most importantly it will unlock a fully funded $25m phase 3 trial in Lupus with blockbuster potential for billion $ sales… Mcap of £17m is far far too low, £50m would still look cheap for the potential on offer here

Some big buys coming in today… can see this going on a big run over the next 2 weeks, I think many people are sitting on the sidelines but it won’t take much for this to shoot back towards 7p ahead of news, sleeping giant looks like it’s waking up from its 3 year slumber… CEO stated he wants to see the price back above 30p in the recent presentation, and if all goes well IMM will be receiving £70m in payments along with £100m annually from Lupozor sales… anyone in sub 6p could easily be looking at life changing gains here, once momentum builds these pharma company’s can shoot crazy to the upside would not be surprised to see this back at £250m Mcap which would be 75p, especially if we get US investors taking a position due to our UD partner Been a private company the only exposure to Lupozor is through IMM… exciting times ahead

Looks like buyers are starting to take positions here ahead of the FDA decision on 29th August, think we will head towards 7p ahead of news, and on a positive decision 15p easily possible here given the ridiculously low Mcap, Avion are paying more for the phase 3 trial than the entire Mcap value of IMM… a huge value disconnect exists here but perhaps not for much longer, exciting times ahead and GL to all holders we are in for quite a ride

Your quite right Ginhall, the unique mechanism of action with Lupozor means there are hardly any side effects which obviously appeals to most people, as Tim mentioned in the presentation $1 billion a year sales in the US alone is highly possible, that’s why IMM hit £250m Mcap during the last phase 3 trial, this time they are fully funded for the trial, have an experienced supportive US partner… yet are valued at sun £16m Mcap the lowest valuation in IMM history… this is so off the radar atm but once investors start to see the value here and momentum builds I feel the rise could be something quite special

Well your making a fool of yourself and it’s embarrassing that’s all I will say, we have a potentially company making announcement 2 weeks today, maybe it would be better to focus on this and what the future could hold, not only for us as shareholders but also for Lupus patients around the world who could benefit from Luzpozer been approved, improving peoples quality of life from a debilitating illness is far more important than increasing our own wealth, hopefully we can do both as they go hand in hand, ATB to all shareholders as we enter the most exciting phase in the recent history of IMM

Wigwammer can I just ask what posting on this board will achieve? Contact Lisa Baderoon head of investor relations, her number is on the most recent rns she will be happy to take your call, because failing that no one on this board is interested in your whining, it’s painful to read tbh, you were wrong when you did t understand what deferred shares meant, you couldn’t add up correctly the amount of shares in issue and embarrassed yourself with your lack of knowledge so now your trying to pick an argument with someone who actually knows what they are talking about in Cuvio. I assume you are no longer invested in IMM and don’t want the FDA to approve the trial in 2 weeks time, fact is we are on countdown now to the FDA decision, positive and 15p can easily be hit intraday imo, Could be an incredible opportunity for those lucky enough to buy in at these all time lows

People on here whining about a few warrants and a random investment no one cares about lol, we are all here because we have a world class drug in Lupozor, that is hopefully about to enter a new optimised phase 3 trial fully funded for $25m by our US partner Avion. Art Deas CEO of Avion predicts Lupozor will be Avion lead drug in the future, quite a statement! Avion and our BOD predict annual sales of $1billion a year in the US alone once Lupozor is fully approved if we ever even got close to this level IMM would be valued north of a billion no problem at all. And that’s without the rest of the world sales, and other indications that Lupozor can be used for such as CIDP. How many companies on aim have this potential? This has been a sleeping giant for 3 years but on 29th August the FDA will make their decision… if they give approval what is a company worth that has a fully funded phase 3 trial for $25m with a drug that has annual sales potential in the billions… we can talk negative all day long but maybe just maybe this will come good and if it does then it could be pretty epic for all involved, GL all

Yep 10 trading days and we will know our fate, the comments from Art Deas regarding Lupozor been the future lead product for Avion was very bullish as was their £1.2m investment in IMM, expect to see a holdings rns after tomorrow which will show they are below 3% due to the dilution from the recent placing, but all shares will be paid up by the end of today so it looks to me like everyone who took the placing did so without leverage as no big sell off today which is a positive

I’d agree with Wigwammer here, when they buy shares they are committing that money for a very very long time, as if they decide to cash in at any point it wouldn’t look good. The fact that Tim took £60k is a positive as he’s never ever taken that amount before and even though I assume he’s well off it’s not a small amount, directors took 10% of the placing not many directors on aim do this so we should at least give them some credit because they didn’t have to, I also must say that Lisa is always happy to have a chat and is very easy to talk to. The most important thing here now is FDA approval in 2 weeks time, that’s the key event in this companies history, good news and this sleeping giant wakes up, the potential has never been in doubt it’s just the delivery… but after a 3 year wait it all comes down to a meeting 2 weeks today to decide the fate of IMM… boom or bust place your bets now it should be one of of a ride

Are you really this thick Wigwammer haha, any money received from Warrants goes to the balance sheet, you cannot possibly work out 47% dilution based on the different prices of the different warrants, tell us all again about the deferred shares your knowledge is wonderful haha

Not a director of Alora I should say

How can Dallo answer that question? He’s an investor no a director of Nolupus, I’d love to meet you Nolupus I bet your a right laugh at parties, if your on Twitter let me know your name

No point arguing on this board, the fact is if the FDA approve the phase 3 trial in 2 weeks time the starting gun will hve been fired and this sleeping giant finally wakes up from its slumber, if the company again reaches an Mcap of £250m as it did previously during the last phase 3 trial all shareholders will be very very happy indeed, IMM has immense potential to change the lives of shareholders from this current all time low level, given the potential of Lupozor. Avion believe in it, Art Deas believes it will be their lead drug, they hve seen every last bit of data, reviewed it countless times, discussed it with the FDA for near 3 years… if they believe in it and are willing to spend $25m to prove it up then I have trust in their foresight, and I would suggest there isn’t anyone on this board who has even 5% of the knowledge of Avion, when it comes to the potential success of Lupozor. We are 10 trading days away from knowing the fate of IMM boom or bust it’s not long to find out, but if it’s boom it could be one hell of a ride

Nolupus, are you as stupid as Wigwammer haha the Mcap is £16m atm if the Mcap gets up to £250m again then that’s a 15 bagger or there abouts, don’t need to divide any shares by anything if the value of the company goes up 15 times to reach £250m Mcap the share price will be 75p

The £250m Mcap is the key figure here, if all goes to plan no reason why this figure cannot be hit once more and that’s a near 20 bagger from this all time low level, it’s the either the opportunity of a lifetime at 5p or tge FDA screw us… 2 weeks to find out

Excellent posts Dallo and from someone who has a significant holding here, this is high risk high reward pharma, if Avion see Lupozor as their future lead drug and see sales of $1bn a year once approved, I don’t think we will be taking about a few million quids worth of warrants if IMM is getting $100m a year in royalties from the US market alone, from one treatment area!! This truly has life changing potential from this level, I mean £16m Mcap, the trial is fully funded for $25m alone!! The FDA approval opens the door for more licensing agreements, funding for the CIDP trial and other indications, this was £250m Mcap during the last phase 3 trial, no reason why this cannot trade in this range once again, history has a habit of repeating itself

Also if warrants or options are exercised then that money goes straight to the balance sheet thus adding value to the company, as Dallo says if Lupozor is successful in the phase 3 trial and gets FDA approval and becomes Avion lead drug as Art Deas has predicted then the future value of IMM will be in the hundreds of millions and most of us who held will be millionaires, 2 weeks time we will find out if the FDA have given approval… we are funded for at least the next 6 months…. BOD took £100k in the placing, all to play for from this all time low level especially those lucky Investors who bought at 5p! If I had any spare funds I would be topping up myself, friend of mine took £30k in the placing and intends to hold for 5 years, boom or bust it’s what aim is all about, GL All, not long until the 29th August, hopefully the starting gun will be fired on this sleeping giant

At last someone who actually understands what they are talking about, good post Cuvio, Wigwammer is clueless and as I suggested to him he should go seek professional advice rather than posting things as fact on this board when he is 100% wrong